Jun‐ya Kato
- Oncology top 0.1%
- Cancer-related Molecular Pathways 50
- Cell Biology top 0.2%
- Microtubule and mitosis dynamics 15
- Molecular Biology top 0.2%
- Ubiquitin and proteasome pathways 37
- Epigenetics and DNA Methylation 12
- RNA modifications and cancer 8
- Cancer Research top 1%
- Biotechnology top 0.5%
- Cancer Research and Treatments 8
-
- Biological Stains and Phytochemicals 10
-
- Curcumin's Biomedical Applications 9
Jun‐ya Kato
125 papers receiving 13.7k citations
Hit Papers
Peers
Comparison fields: 5 of 131
- Oncology 8.0k
- Cell Biology 2.7k
- Molecular Biology 10.2k
- Cancer Research 1.4k
- Biotechnology 756
Countries citing papers authored by Jun‐ya Kato
This map shows the geographic impact of Jun‐ya Kato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun‐ya Kato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun‐ya Kato more than expected).
Fields of papers citing papers by Jun‐ya Kato
This network shows the impact of papers produced by Jun‐ya Kato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun‐ya Kato. The network helps show where Jun‐ya Kato may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jun‐ya Kato, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 1 | |
| 3 | 2023 | 4 | |
| 4 | 2023 | 2 | |
| 5 | 2023 | 7 | |
| 6 | 2022 | 2 | |
| 7 | 2021 | 14 | |
| 8 | 2016 | 14 | |
| 9 | 2013 | 0 | |
| 10 | 2013 | 38 | |
| 11 | 2011 | 1 | |
| 12 | 2011 | 2 | |
| 13 | 2007 | 0 | |
| 14 | 2006 | 9 | |
| 15 | 2004 | 1 | |
| 16 | 2002 | 13 | |
| 17 | Novel INK4 Proteins, p19 and p18, Are Specific Inhibitors of the Cyclin D-Dependent Kinases CDK4 and CDK6breakdown → | 1995 | 533 |
| 18 | 1994 | 305 | |
| 19 | Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4breakdown → | 1993 | 1065 |
| 20 | 1986 | 17 |
About Jun‐ya Kato
Jun‐ya Kato is a scholar working on Oncology, Molecular Medicine, Molecular Biology, Biotechnology and Cell Biology, having authored 129 papers that have together received 14.0k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (50 papers), Ubiquitin and proteasome pathways (37 papers), Microtubule and mitosis dynamics (15 papers), Epigenetics and DNA Methylation (12 papers), Biological Stains and Phytochemicals (10 papers), Curcumin's Biomedical Applications (9 papers), Cancer Research and Treatments (8 papers) and RNA modifications and cancer (8 papers). The work is most often cited by research in Oncology (8.0k citations), Cell Biology (2.7k citations), Molecular Biology (10.2k citations), Cancer Research (1.4k citations) and Biotechnology (756 citations). Jun‐ya Kato has collaborated with scholars based in Japan, United States and Indonesia. Frequent co-authors include Charles J. Sherr, Mark E. Ewen, C J Sherr, Martine F. Roussel, H Matsushime, Joan Massagué, Kornélia Polyák, Dawn E. Quelle, Sheila Shurtleff and Hitoshi Matsushime. Their work appears in journals such as Molecular and Cellular Biology, Journal of Biological Chemistry, FEBS Letters, Scientific Reports and Advanced Pharmaceutical Bulletin.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.